BCAX
Bicara Therapeutics

79
Mkt Cap
$1.23B
Volume
242,939.00
52W High
$20.25
52W Low
$7.80
PE Ratio
-8.70
BCAX Fundamentals
Price
$19.32
Prev Close
$19.40
Open
$19.30
50D MA
$16.87
Beta
1.76
Avg. Volume
504,042.94
EPS (Annual)
-$1.25
P/B
2.63
Rev/Employee
$0.00
$459.37
Loading...
Loading...
News
all
press releases
Cantor Fitzgerald L. P. Invests $1.58 Million in Bicara Therapeutics Inc. $BCAX
Cantor Fitzgerald L. P. purchased a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the third quarter, according to its most recent disclosure with the Securities...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference
Bicara Therapeutics (NASDAQ:BCAX) is developing tumor-targeting bifunctional antibodies, with its lead candidate ficerasfusp alfa designed to address both EGFR and TGF-beta biology in cancer, company...
MarketBeat·5d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $704,804.22 in Stock
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 36,766 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of...
MarketBeat·5d ago
News Placeholder
Claire Mazumdar Sells 36,766 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 36,766 shares of the company's stock in a transaction on Monday, March 9th. The stock was sold at an average price of...
MarketBeat·6d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 1-Year High - Here's What Happened
Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year High - Still a Buy...
MarketBeat·8d ago
News Placeholder
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells 1,786 Shares of Stock
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock in a transaction that occurred on Thursday, March 5th. The shares were sold...
MarketBeat·10d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $49,278.63 in Stock
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 2,631 shares of the firm's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of...
MarketBeat·11d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $33,469.64 in Stock
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 1,786 shares of the business's stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an...
MarketBeat·11d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 3,817 Shares
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 3,817 shares of the stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price...
MarketBeat·11d ago
News Placeholder
Ivan Hyep Sells 13,555 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 13,555 shares of the business's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an...
MarketBeat·11d ago
<
1
2
...
>

Latest BCAX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.